Toxicological considerations for intravitreal drugs

Toxicological considerations for intravitreal drugs

Author Penha, Fernando M. Autor UNIFESP Google Scholar
Rodrigues, Eduardo B. Autor UNIFESP Google Scholar
Furlani, Bruno A. Autor UNIFESP Google Scholar
Dib, Eduardo Autor UNIFESP Google Scholar
Melo, Gustavo B. Autor UNIFESP Google Scholar
Farah, Michel E. Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Abstract Introduction: Intravitreal injections are a very common procedure and are the most effective route of drug delivery to the retina. There are currently several drugs available and even more are in development; therefore, safety is a very important concern.Areas covered: the toxicological considerations of the most common drugs used for intravitreal pharmacotherapy such as anti-VEGFs, corticosteroids and antibiotics. Emerging agents such as anti-TNFs, VEGF-trap and kinase inhibitors are also discussed. An assessment of the efficacy and safety issues of the most relevant drugs including bevacizumab, ranibizumab and triamcinolone is presented.Expert opinion: the toxicology and safety profiles are available for several drugs that are either in use or will be available for intravitreal injections. Retinal pharmacotherapy is very effective for different retinal diseases; however safety is a very important issue when intravitreal injections are applied and the possibility of retinal toxicity should always be kept in mind. Bevacizumab and ranibizumab are effective for the therapy of wet-age-related macular degeneration and macular edema, while triamcinolone remains an alternative agent to treat secondary macular edema. It is important, as some of these drugs will be used for extended periods of time, that their long-term toxicological effects are better understood.
Keywords bevacizumab
monoclonal antibodies
retinal pharmacotherapy
tumor necrosis factor
vascular endothelial growth factor
Language English
Date 2011-08-01
Published in Expert Opinion On Drug Metabolism & Toxicology. London: Informa Healthcare, v. 7, n. 8, p. 1021-1034, 2011.
ISSN 1742-5255 (Sherpa/Romeo, impact factor)
Publisher Informa Healthcare
Extent 1021-1034
Access rights Closed access
Type Review
Web of Science ID WOS:000292840100007

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account